Metharbital

Metharbital is a barbiturate that was first synthesized in Germany in 1905. It is used as a long-acting sedative and hypnotic. Metharbital is currently a Schedule III drug under the Controlled Substances Act in the United States. Its LD50 in mice is 2500 mg/kg.

History[edit | edit source]

Metharbital was first synthesized in Germany in 1905 and was marketed under the trade name Gemonil. It was used as a long-acting sedative and hypnotic until the 1970s, when it was replaced by newer drugs with improved safety profiles.

Pharmacology[edit | edit source]

Metharbital works by increasing the activity of the GABA neurotransmitter in the brain, which produces a calming effect. It is metabolized in the liver and excreted in the urine.

Side effects[edit | edit source]

Common side effects of metharbital include drowsiness, dizziness, and loss of coordination. More serious side effects can include confusion, hallucinations, and addiction.

Legal status[edit | edit source]

In the United States, metharbital is a Schedule III drug under the Controlled Substances Act. This means it has a potential for abuse less than drugs in Schedules I and II, but abuse may lead to moderate or low physical dependence or high psychological dependence.

See also[edit | edit source]

Metharbital Resources
Need Help Finding a Doctor? Need help finding a doctor or specialist anywhere in the world? Explore our world directory. WikiMD's DocFinder can assist you in locating millions of physicians.	Medical Knowledge Access the latest research - Most recent articles Ongoing trials.